Cheryl Arrowsmith

Cheryl Arrowsmith
NationalityCanadian
Alma materUniversity of Toronto
Scientific career
FieldsStructural biology
InstitutionsStructural Genomics Consortium

Cheryl H. Arrowsmith is a Canadian structural biologist and is the Chief Scientist at the Toronto laboratory of the Structural Genomics Consortium. Her contributions to protein structural biology[1] includes the use of NMR and X-ray crystallography to pursue structures of proteins on a proteome wide scale.

She received her Ph.D. in chemistry at the University of Toronto in 1987 and post-doctoral training at Stanford University working with Oleg Jardetzky. One of her areas of interest is the tumour suppressor p53 and related proteins.[2]

Her current research is to determine the 3-dimensional structures of human proteins of therapeutic relevance by structural proteomics.[3] She has made significant contributions to epigenetic signaling in the context of drug discovery.[4]

Arrowsmith was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2015.[5] She was also named as one of the Clarivate Highly Cited Researchers in 2023.[6]

  1. ^ "Cheryl H. Arrowsmith". uhnresearch.ca. Retrieved December 27, 2017.
  2. ^ "Cheryl Arrowsmith". utoronto.ca. Retrieved December 27, 2017.
  3. ^ Chandonia JM, Brenner SE (January 2006). "The impact of structural genomics: expectations and outcomes". Science. 311 (5759): 347–51. Bibcode:2006Sci...311..347C. doi:10.1126/science.1121018. PMID 16424331. S2CID 800902.
  4. ^ Cheryl H. Arrowsmith, Chas Bountra, Paul V. Fish, Kevin Lee & Matthieu Schapira. Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery 11, 384–400 (2012)
  5. ^ "Arrowsmith named AAAS Fellow". utoronto.ca. Retrieved December 27, 2017.
  6. ^ "Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List". Clarivate. 2023-11-15. Retrieved 2024-01-03.